About: CD147 as a Target for COVID-19 Treatment: Suggested Effects of Azithromycin and Stem Cell Engagement

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: CD147 as a Target for COVID-19 Treatment: Suggested Effects of Azithromycin and Stem Cell Engagement Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	CD147 as a Target for COVID-19 Treatment: Suggested Effects of Azithromycin and Stem Cell Engagement
Creator	Ulrich, Henning Pillat, Micheli
Source	Medline; PMC
abstract	The expressive number of deaths and confirmed cases of SARS-CoV-2 call for an urgent demand of effective and available drugs for COVID-19 treatment. CD147, a receptor on host cells, is a novel route for SARS-CoV-2 invasion. Thus, drugs that interfere in the spike protein/CD147 interaction or CD147 expression may inhibit viral invasion and dissemination among other cells, including in progenitor/stem cells. Studies suggest beneficial effects of azithromycin in reducing viral load of hospitalized patients, possibly interfering with ligand/CD147 receptor interactions; however, its possible effects on SARS-CoV-2 invasion has not yet been evaluated. In addition to the possible effect in invasion, azithromycin decreases the expression of some metalloproteinases (downstream to CD147), induces anti-viral responses in primary human bronchial epithelial infected with rhinovirus, decreasing viral replication and release. Moreover, resident lung progenitor/stem are extensively differentiated into myofibroblasts during pulmonary fibrosis, a complication observed in COVID-19 patients. This process, and the possible direct viral invasion of progenitor/stem cells via CD147 or ACE2, could result in the decline of these cellular stocks and failing lung repair. Clinical tests with allogeneic MSCs from healthy individuals are underway to enhance endogenous lung repair and suppress inflammation.
has issue date	2020-04-20(xsd:dateTime)
bibo:doi	10.1007/s12015-020-09976-7
bibo:pmid	32307653
has license	no-cc
sha1sum (hex)	58354b3b864d1b268f4151740019a5a8ff994d34
schema:url	https://doi.org/10.1007/s12015-020-09976-7
resource representing a document's title	CD147 as a Target for COVID-19 Treatment: Suggested Effects of Azithromycin and Stem Cell Engagement
has PubMed Central identifier	PMC7167302
has PubMed identifier	32307653
schema:publication	Stem Cell Rev Rep
resource representing a document's body	covid:58354b3b864d1b268f4151740019a5a8ff994d34#body_text
is schema:about of	named entity 'anti-viral' named entity 'differentiated' named entity 'protein' named entity 'endogenous' named entity 'induces' named entity 'viral' named entity 'Target' named entity 'drugs' named entity 'patients' named entity 'expressive' named entity 'This' named entity 'bronchial' named entity 'invasion' named entity 'cellular' named entity 'receptor' named entity 'chronic inflammatory conditions' named entity 'peripheral blood mononuclear cells' named entity 'COVID' named entity 'infection' named entity 'interaction' named entity 'stocks' named entity 'tests' named entity 'interfere' named entity 'Engagement' named entity 'inflammation' named entity 'ACE2' named entity 'ligand' named entity 'endogenous' named entity 'lung' named entity 'spike protein' named entity 'Azithromycin' named entity 'ligand' named entity 'Pneumonia' named entity 'COVID-19' named entity 'bone marrow' named entity 'Lung' named entity 'ACE2' named entity 'coronavirus 2' named entity 'GLI1' named entity 'Stem cells' named entity 'CD147' named entity 'clinical trials' named entity 'Plasmodium falciparum' named entity 'EMMPRIN' named entity 'SARS-CoV-2' named entity 'SARS-CoV-2' named entity 'protein' named entity 'ACE2' named entity 'COVID-19' named entity 'macrophages' named entity 'SARS-CoV' named entity 'pulmonary fibrosis' named entity 'pathogenesis' named entity 'epithelial cells' named entity 'diabetic complications' named entity 'lung' named entity 'azithromycin' named entity 'MSC' named entity 'molecule' named entity 'alveolar' named entity 'tropism' named entity 'COVID' named entity 'CD147' named entity 'RBC' named entity 'lung fibrosis' named entity 'azithromycin' named entity 'antibiotic' named entity 'type II pneumocyte' named entity 'CD147' named entity 'lung disease' named entity 'COVID-19' named entity 'clinical trial' named entity 'antibiotic' named entity 'infection' named entity 'CD147' named entity 'SARS' named entity 'ACE2' named entity 'azithromycin' named entity 'alveolar' named entity 'receptor'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software